Quadrant Capital Group’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $386K | Hold |
7,474
| – | – | 0.01% | 1022 |
|
|
2025
Q4 | $371K | Sell |
7,474
-23
| -0.3% | -$1.12K | 0.01% | 1061 |
|
|
2025
Q3 | $358K | Buy |
7,497
+5
| +0.1% | +$201 | 0.01% | 1050 |
|
|
2025
Q2 | $236K | Buy |
7,492
+705
| +10% | +$22.6K | 0.01% | 1239 |
|
|
2025
Q1 | $222K | Buy |
6,787
+5,316
| +361% | +$188K | 0.01% | 1241 |
|
|
2024
Q4 | $53.2K | Hold |
1,471
| – | – | ﹤0.01% | 1379 |
|
|
2024
Q3 | $45.9K | Hold |
1,471
| – | – | ﹤0.01% | 1494 |
|
|
2024
Q2 | $39.4K | Sell |
1,471
-817
| -36% | -$23.7K | ﹤0.01% | 1527 |
|
|
2024
Q1 | $78K | Buy |
2,288
+839
| +58% | +$25K | 0.01% | 1140 |
|
|
2023
Q4 | $41.9K | Buy |
1,449
+1,330
| +1,118% | +$35.3K | ﹤0.01% | 1487 |
|
|
2023
Q3 | $3.28K | Sell |
119
-188
| -61% | -$5.72K | ﹤0.01% | 2275 |
|
|
2023
Q2 | $9.23K | Buy |
307
+38
| +14% | +$1.33K | ﹤0.01% | 2026 |
|
|
2023
Q1 | $9.75K | Buy |
269
+100
| +59% | +$3.85K | ﹤0.01% | 2034 |
|
|
2022
Q4 | $6.03K | Sell |
169
-373
| -69% | -$13K | ﹤0.01% | 2160 |
|
|
2022
Q3 | $18K | Buy |
542
+400
| +282% | +$13K | ﹤0.01% | 1618 |
|
|
2022
Q2 | $4K | Buy |
142
+13
| +10% | +$372 | ﹤0.01% | 2056 |
|
|
2022
Q1 | $4K | Hold |
129
| – | – | ﹤0.01% | 1996 |
|
|
2021
Q4 | $4K | Sell |
129
-21
| -14% | -$637 | ﹤0.01% | 1973 |
|
|
2021
Q3 | $4K | Buy |
150
+14
| +10% | +$376 | ﹤0.01% | 1966 |
|
|
2021
Q2 | $4K | Buy |
136
+7
| +5% | +$215 | ﹤0.01% | 1944 |
|
|
2021
Q1 | $3K | Hold |
129
| – | – | ﹤0.01% | 1990 |
|
|
2020
Q4 | $3K | Buy |
129
+21
| +19% | +$452 | ﹤0.01% | 1870 |
|
|
2020
Q3 | $2K | Hold |
108
| – | – | ﹤0.01% | 1862 |
|
|
2020
Q2 | $3K | Hold |
108
| – | – | ﹤0.01% | 1841 |
|
|
2020
Q1 | $2K | Buy |
108
+47
| +77% | +$988 | ﹤0.01% | 1902 |
|
|
2019
Q4 | $1K | Hold |
61
| – | – | ﹤0.01% | 2354 |
|
|
2019
Q3 | $1K | Sell |
61
-797
| -93% | -$23.6K | ﹤0.01% | 2224 |
|
|
2019
Q2 | $28K | Buy |
858
+797
| +1,307% | +$27.3K | ﹤0.01% | 1498 |
|
|
2019
Q1 | $2K | Hold |
61
| – | – | ﹤0.01% | 2092 |
|
|
2018
Q4 | $2K | Hold |
61
| – | – | ﹤0.01% | 1944 |
|
|
2018
Q3 | $3K | Sell |
61
-38
| -38% | -$1.88K | ﹤0.01% | 1757 |
|
|
2018
Q2 | $5K | Buy |
99
+38
| +62% | +$1.97K | ﹤0.01% | 1579 |
|
|
2018
Q1 | $2K | Sell |
61
-43
| -41% | -$1.79K | ﹤0.01% | 1887 |
|
|
2017
Q4 | $3K | Hold |
104
| – | – | ﹤0.01% | 1685 |
|
|
2017
Q3 | $3K | Buy |
104
+43
| +70% | +$1.86K | ﹤0.01% | 1685 |
|
|
2017
Q2 | $0 | Hold |
61
| – | – | ﹤0.01% | 2051 |
|
|
2017
Q1 | $1K | Hold |
61
| – | – | ﹤0.01% | 1885 |
|
|
2016
Q4 | $1K | Buy |
+61
| New | +$1.36K | ﹤0.01% | 1804 |
|
|
2016
Q1 | – | Sell |
-142
| Closed | -$1K | – | 1974 |
|
|
2015
Q4 | $1K | Hold |
142
| – | – | ﹤0.01% | 1474 |
|
|
2015
Q3 | $1K | Hold |
142
| – | – | ﹤0.01% | 1114 |
|
|
2015
Q2 | $1K | Buy |
+142
| New | +$2.02K | ﹤0.01% | 1091 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Quadrant Capital Group's SUPN Position: Q1 2026 in Review
Quadrant Capital Group held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 7,474 shares worth $386K. The position accounts for 0.01% of the portfolio, ranked #1022.
Quadrant Capital Group first reported a position in SUPN in Q2 2015 and has held it in 41 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Quadrant Capital Group held 7,474 shares of Supernus Pharmaceuticals worth $386K as of Q1 2026.
- Quadrant Capital Group left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
- Supernus Pharmaceuticals made up 0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1022 holding.
- Quadrant Capital Group first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 41 quarters since.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.